Clinical Trial Update: Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating autologous immune killer cells as an adjunct therapy for liver cancer (hepatocellular carcinoma).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Liver Cancer

Drugs mentioned

• Autologous Immune Killer Cells

Snippet

Sponsor: Ivy Life Sciences, Co., Ltd | Conditions: HepatoCellular Carcinoma, Liver Cancer | Phase 2, Phase 3 | Status: UNKNOWN